findmyKOL
Clinical trialNCT03200847CompletedPhase 1/PHASE2Interventional

Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

SponsorUniversity of Colorado, DenverEnrollment26Advanced MelanomaStage III MelanomaStage IV Melanoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase I/Ib investigator-initiated open label of the combination of VESANOID and pembrolizumab treatment.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Colorado Denver

    Aurora, Colorado, United States

  • Poudre Valley Hospital

    Fort Collins, Colorado, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pembrolizumab with All-Trans Retinoic Acid
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Oct 2017
Primary completion
20 Jul 2022
Completion
19 Oct 2022
Last update posted
1 Oct 2024
Registered enrollment
26
Registry id
NCT03200847
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.